PMID- 34535141
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210921
IS  - 1475-2867 (Print)
IS  - 1475-2867 (Electronic)
IS  - 1475-2867 (Linking)
VI  - 21
IP  - 1
DP  - 2021 Sep 17
TI  - Primary breast double-hit lymphoma management and outcomes: a real-world 
      multicentre experience.
PG  - 498
LID - 10.1186/s12935-021-02198-y [doi]
LID - 498
AB  - BACKGROUND: Primary breast double-hit lymphoma (PB-DHL) is a rare, highly 
      aggressive malignancy that poses challenges regarding accurate diagnosis and 
      selecting optimal treatment regimens. METHODS: We retrospectively reviewed 48 
      cases of patients diagnosed with PB-DHL in six academic centres between June 2014 
      and June 2020 in China. Study-specific data were recorded, including treatment 
      options, therapeutic evaluation, prognostic factors and relapse patterns, and the 
      overall survival (OS) and progression-free survival (PFS) were evaluated. 
      RESULTS: In total, 48 patients were enrolled, with 14 patients treated with 
      DA-EPOCH-R/MA (rituximab, dose-adjusted etoposide, prednisone, vincristine, 
      cyclophosphamide, doxorubicin, alternating with high-dose methotrexate and 
      cytarabine), 18 patients treated with DA-EPOCH-R (rituximab, dose-adjusted 
      etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin), and 16 
      patients treated with R-HyperCVAD (rituximab, hyperfractionated cyclophosphamide, 
      vincristine, doxorubicin, dexamethasone, alternating with cytarabine plus 
      methotrexate). The overall 5-year OS and PFS rates were 41.7% (95% confidence 
      interval [CI], 27.6-56.8%) and 37.5% (95% CI, 24.0-52.6%), respectively. Of the 
      three treatment regimens, the 5-year OS was higher in DA-EPOCH-R/MA group than in 
      the DA-EPOCH-R or R-HyperCVAD subgroups (57.1% vs. 38.9% vs. 31.3%; P = 0.016), 
      as was the 5-year PFS (50.0% vs. 38.9% vs. 25.0%; P = 0.035). Autologous stem 
      cell transplantation (ASCT) prolonged the OS and PFS compared with non-ASCT 
      patients (5-year OS: 72.2% vs. 23.3%; P < 0.001; 5-year PFS: 72.2% vs. 16.7 %, 
      P < 0.001). Multivariate analysis identified tumour size, risk stratification, 
      treatment with DA-EPOCH-R/MA, breast irradiation, and ASCT as significant 
      prognostic factors. CONCLUSIONS: DA-EPOCH-R/MA is a promising regimen for PB-DHL, 
      and breast irradiation yields complementary benefits for prognosis. ASCT 
      significantly decreased disease relapse, providing a potential curative PB-DHL 
      intervention and justifying ASCT as first-line therapy for young patients. More 
      effective treatment strategies for PB-DHL patients remain encouraging.
CI  - (c) 2021. The Author(s).
FAU - Zhang, Tingting
AU  - Zhang T
AD  - Haematopoietic Stem Cell Transplantation Centre, State Key Laboratory of 
      Experimental Hematology, National Clinical Research centre for Blood Diseases, 
      Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical 
      Sciences and Peking Union Medical College, No. 288 Nanjing Road, Tianjin, 300020, 
      China.
FAU - Zhang, Yuanfeng
AU  - Zhang Y
AD  - Haematopoietic Stem Cell Transplantation Centre, State Key Laboratory of 
      Experimental Hematology, National Clinical Research centre for Blood Diseases, 
      Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical 
      Sciences and Peking Union Medical College, No. 288 Nanjing Road, Tianjin, 300020, 
      China.
AD  - Department of Haematology, The Affiliated Yantai Yuhuangding Hospital of Qingdao 
      University, Yantai, 264000, Shandong, China.
FAU - Fei, Hairong
AU  - Fei H
AD  - Department of Haematology, The Affiliated Hospital of Qingdao University, 
      Qingdao, 266003, Shandong, China.
FAU - Shi, Xue
AU  - Shi X
AD  - Department of Haematology, The Affiliated Hospital of Qingdao University, 
      Qingdao, 266003, Shandong, China.
FAU - Wang, Liang
AU  - Wang L
AD  - Department of Haematology, Shengli Oilfield Central Hospital, Dongying, 257000, 
      China.
FAU - Wang, Peijun
AU  - Wang P
AD  - Department of Haematology, Qingdao Centre Hospital, Qingdao, 266042, Shandong, 
      China.
FAU - Yu, Jie
AU  - Yu J
AD  - Department of Haematology, Weihai Municipal Hospital, Weihai, 264200, Shandong, 
      China.
FAU - Shen, Yuyan
AU  - Shen Y
AD  - Haematopoietic Stem Cell Transplantation Centre, State Key Laboratory of 
      Experimental Hematology, National Clinical Research centre for Blood Diseases, 
      Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical 
      Sciences and Peking Union Medical College, No. 288 Nanjing Road, Tianjin, 300020, 
      China. shenyuyan@ihcams.ac.cn.
FAU - Feng, Sizhou
AU  - Feng S
AUID- ORCID: 0000-0001-5304-3301
AD  - Haematopoietic Stem Cell Transplantation Centre, State Key Laboratory of 
      Experimental Hematology, National Clinical Research centre for Blood Diseases, 
      Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical 
      Sciences and Peking Union Medical College, No. 288 Nanjing Road, Tianjin, 300020, 
      China. doctor_szhfeng@sina.com.
LA  - eng
GR  - 81900182/national outstanding youth foundation of china/
PT  - Journal Article
DEP - 20210917
PL  - England
TA  - Cancer Cell Int
JT  - Cancer cell international
JID - 101139795
PMC - PMC8447786
OTO - NOTNLM
OT  - Double-hit lymphoma
OT  - High-grade B-cell lymphomas
OT  - Primary breast lymphoma
OT  - Prognosis
OT  - Relapse
OT  - Therapy
COIS- All authors declared no competing interests.
EDAT- 2021/09/19 06:00
MHDA- 2021/09/19 06:01
PMCR- 2021/09/17
CRDT- 2021/09/18 05:26
PHST- 2021/06/10 00:00 [received]
PHST- 2021/09/06 00:00 [accepted]
PHST- 2021/09/18 05:26 [entrez]
PHST- 2021/09/19 06:00 [pubmed]
PHST- 2021/09/19 06:01 [medline]
PHST- 2021/09/17 00:00 [pmc-release]
AID - 10.1186/s12935-021-02198-y [pii]
AID - 2198 [pii]
AID - 10.1186/s12935-021-02198-y [doi]
PST - epublish
SO  - Cancer Cell Int. 2021 Sep 17;21(1):498. doi: 10.1186/s12935-021-02198-y.